The board of directors of the Company (the "Board") announced that submission of a New Drug Application (NDA) to the Department of Health, the Hong Kong Special Administrative Region, China, for XeravaTM (eravacycline) for the treatment of complicated intra-abdominal infections ("cIAI") in adult patients in Hong Kong. XeravaTM is currently approved for the treatment of cIAI in the United States ("US"), Europe ("EU"), United Kingdom ("UK") and Singapore, and is currently under regulatory review for the treatment of cIAI in China. In September 2020, XeravaTM was included in the Infectious Disease Society of America's (IDSA) updated clinical guidelines on the treatment of antimicrobial resistant gram-negative infections and in March 2021, it was included in an expert consensus on the multidisciplinary management of intra-abdominal infections by the Chinese Society of Surgery of Chinese Medical Association, Infectious Diseases Society for Evidence-based and Chinese Research Hospital Association and the Editorial Board of Chinese Journal of Surgery. Complicated intra-abdomnal infections (cIAI) is a type of major hospital- or community-acquired infection which extend beyond the source organ into the peritoneal space and can result from perforation of or damage to the gastrointestinal tract. cIAI diagnoses include intra-abdominal abscess, stomach or intestinal perforation, peritonitis, appendicitis, cholecystitis, or diverticulitis. cIAI is caused by different bacterial pathogens, including gram-negative aerobic bacteria, gram- positive bacteria, and anaerobic bacteria. In 2018, there were 2.9 million cIAI patients in China alone, with increasing rates of infections caused by drug-resistant bacteria, which limits the effectiveness of currently available antibiotics. XeravaTM (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against gram-negative and gram-positive pathogens that have acquired multidrug resistance and are prevalent in China. XeravaTM is currently approved for the treatment of cIAI in the US, EU, UK and Singapore and the medicine is currently under review for the treatment of cIAI in China. The Company is also developing XeravaTM for the treatment of community-acquired bacterial pneumonia. XeravaTM was licensed from Tetraphase Pharmaceuticals Inc., now a wholly owned subsidiary of La Jolla Pharmaceutical Company.